EP 4155308 A4 20240417 - ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Title (en)
ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Title (de)
GESTEINSINHIBITOR SOWIE HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON
Title (fr)
INHIBITEUR DE ROCK, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
Publication
Application
Priority
- CN 202010676711 A 20200714
- CN 202110040185 A 20210111
- CN 2021105263 W 20210708
Abstract (en)
[origin: EP4155308A1] A ROCK inhibitor represented by formula (I), and a preparation method therefor and a use thereof. The ROCK inhibitor has excellent ROCK inhibition activity, particularly shows good selective inhibition on ROCK2 kinase, has good safety and metabolic stability, and is high in bioavailability. The preparation method for the ROCK inhibitor is simple, and the ROCK inhibitor is easy to purify, and therefore has a good application prospect.
IPC 8 full level
C07D 231/12 (2006.01); A61K 31/395 (2006.01); A61K 31/506 (2006.01); A61P 3/08 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01)
CPC (source: CN EP US)
A61P 1/16 (2018.01 - CN); A61P 3/08 (2018.01 - EP); A61P 3/10 (2018.01 - CN); A61P 7/02 (2018.01 - CN); A61P 9/00 (2018.01 - CN EP); A61P 9/04 (2018.01 - CN); A61P 9/10 (2018.01 - CN); A61P 9/12 (2018.01 - CN); A61P 11/00 (2018.01 - CN); A61P 11/06 (2018.01 - CN); A61P 13/12 (2018.01 - CN); A61P 15/10 (2018.01 - CN); A61P 17/16 (2018.01 - CN); A61P 19/10 (2018.01 - CN); A61P 25/00 (2018.01 - CN); A61P 27/02 (2018.01 - CN); A61P 27/06 (2018.01 - CN); A61P 29/00 (2018.01 - CN); A61P 35/00 (2018.01 - CN EP); A61P 37/00 (2018.01 - CN); C07D 231/12 (2013.01 - EP US); C07D 401/14 (2013.01 - CN EP US); C07D 403/12 (2013.01 - EP); C07D 403/14 (2013.01 - CN EP US); C07D 471/04 (2013.01 - CN EP US); C07D 487/04 (2013.01 - CN EP US); C07D 519/00 (2013.01 - CN EP US)
Citation (search report)
- [XI] WO 2020094111 A1 20200514 - BEIJING TIDE PHARMACEUTICAL CO LTD [CN]
- [XI] WO 2009050236 A1 20090423 - BOEHRINGER INGELHEIM INT [DE], et al
- [X] WO 2008068171 A1 20080612 - HOFFMANN LA ROCHE [CH], et al
- [X] WO 2004096810 A1 20041111 - PFIZER LTD [GB], et al
- [X] US 2019276440 A1 20190912 - ZHAO YANPING [CN], et al
- [XI] WO 2019000682 A1 20190103 - BEIJING TIDE PHARMACEUTICAL CO LTD [CN]
- [XI] WO 2019000683 A1 20190103 - BEIJING TIDE PHARMACEUTICAL CO LTD [CN]
- [XP] EP 3845276 A1 20210707 - IND TECH RES INST [TW]
- [X] WO 2019045824 A1 20190307 - KADMON CORP LLC [US]
- [X] WO 02079187 A1 20021010 - DONG WHA PHARM IND CO LTD [KR], et al
- [X] WO 0125220 A1 20010412 - KINETIX PHARMACEUTICALS INC [US], et al
- [X] WO 2016210330 A1 20161229 - KADMON CORP LLC [US]
- [X] WO 2016210331 A1 20161229 - KADMON CORP LLC [US]
- [X] WO 2018201006 A1 20181101 - KADMON CORP LLC [US]
- [XP] WO 2020185044 A1 20200917 - VORONOI CO LTD [KR], et al
- [X] LIU KEVIN G. ET AL: "Discovery and Optimization of Glucose Uptake Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 10, 13 April 2020 (2020-04-13), US, pages 5201 - 5211, XP093137311, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b02153
- See also references of WO 2022012409A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
EP 4155308 A1 20230329; EP 4155308 A4 20240417; AU 2021309876 A1 20230223; AU 2021309876 B2 20240627; CA 3184616 A1 20220120; CN 113929678 A 20220114; JP 2023534259 A 20230808; KR 20230038697 A 20230321; MX 2023000630 A 20230315; TW 202214628 A 20220416; US 2023257376 A1 20230817; WO 2022012409 A1 20220120
DOCDB simple family (application)
EP 21842081 A 20210708; AU 2021309876 A 20210708; CA 3184616 A 20210708; CN 2021105263 W 20210708; CN 202110776971 A 20210708; JP 2023502738 A 20210708; KR 20237000774 A 20210708; MX 2023000630 A 20210708; TW 110125960 A 20210714; US 202118005165 A 20210708